System Biosciences LLC

Company Overview

Exosomics S.p.A is a biotechnology company focused on harnessing the power of EVs and exosomes for research and clinical applications. The company’s investors include Lonza, Agilent Technologies, BioBalt Holding, Black Swan Trade Ltd., Finbiotech Srl, and LCM Genect Srl. The company operates through two subsidiaries, Rivela Diagnostics and HansaBioMed Life Sciences.

Founded in 2022, Rivela Diagnostics Ltd. is developing a blood test for multi-cancer early detection exploiting circulating exosomes as a biomarker for cancer-specific alterations of cell metabolism.

Exosomics acquired HansaBioMed Life Sciences in 2019. Founded in 2007, HansaBioMed Life Sciences develops and commercializes proprietary platforms, kits, reagents, and equipment for exosome research in the life science market. Its service portfolio includes scalable and automated purification of EVs from conditioned media, biofluids or plant extracts, bulk or single EV characterization, biomarker assessment by mass spectrometry, and RNA seq. The catalog of products includes a broad range of purified EVs and tools for EV purification, enrichment, and characterization. HansaBioMed Life Sciences facilities are in Tallinn (Estonia) and the Technology Park Tehnopol.

Company's Business Segments

• Products : The company generates revenue from several product categories such as, Exosome Research, CRISPR/Cas9 Systems, Lentivirus Production, Gene Expression Systems, Imaging and Reporter Vectors, miRNA and IncRNA Research Tools, Liquid Biopsy Research, Covid-19 Research Tools.
• Services : The company generates revenue by providing various services such as Custom Services, Exsome Services, Syn2Clone Custome Constructs, Lentivirus Packaging, Stable Cell Lines, RNA Services, Minicircle Services, CRISPR/Cas9 Services.